Enhancing the QUAlity and Transparency Of health Research
Search for reporting guidelines
Use your browser's Back button to return to your search results
Benefit -Risk Assessment of Vaccines. Part II : Proposal Towards Consolidated Standards of Reporting Quantitative Benefit -Risk Models Applied to Vaccines (BRIVAC)
| Reporting guideline provided for? (i.e. exactly what the authors state in the paper) |
Reporting of vaccine quantitative benefit-risk model (qBRm) research. |
| Full bibliographic reference | Arlegui H, Bollaerts K, Bauchau V, Nachbaur G, Bégaud B, Praet N. Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC). Drug Saf. 2020;1-16. |
| Language | English |
| PubMed ID | 32918682 |
| Relevant URLs (full-text if available) |
The full-text of the BRIVAC reporting guideline is available at: https://link.springer.com/article/10.1007%2Fs40264-020-00982-9 The BRIVAC checklist can be accessed at: https://link.springer.com/article/10.1007/s40264-020-00982-9/tables/2 |
| Reporting guideline acronym | BRIVAC |
| Clinical area | Infectious diseases, Pharmaceutical medicine, Public health |
| Applies to the whole report or to individual sections of the report? | Whole report |
| Record last updated on | October 2, 2020 |